NEW YORK – Renovaro Biosciences on Wednesday said it will merge with GEDi Cube and use the company's artificial intelligence technology to accelerate its existing clinical pipeline and discover new biomarker-directed cancer therapies.
Los Angeles-based Renovaro is currently focused on developing treatments for pancreatic cancer and plans to begin Phase I/IIa clinical studies by mid-2024, including for solid tumors with short life expectancy. Amsterdam-based GEDi Cube has developed an AI machine learning platform that conducts multiomics analysis and has a library of more than 2,600 biomarker panels to support the discovery and development of precision oncology treatments. The company said it has validated this AI platform for diagnosing lung cancer early and is working on expanding the technology's diagnostic capabilities into other cancers and diseases.
The companies have executed a letter of intent to merge but have not disclosed any financial details of the proposed deal.
Renovaro stated that GEDi's AI technology will allow it to zero in on cancers most likely to respond to treatments it is developing and identify biomarkers for diagnosing disease and monitoring disease progression. The companies are also optimistic that GEDi's AI technology will help shepherd Renovaro's immune-directed preclinical programs to the clinic.
"I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our lifesaving technology to more cancer patients and renewing hope for them and their families," Renovaro CEO Mark Dybul said in a statement.